PDCD1 and neoplasm: By targeting both CTLA-4 and PD-1, these bispecific antibodies can simultaneously promote activation and proliferation of T cells, reduce regulatory T cell function, and enhance the killing of tumor cells by cytotoxic T lymphocytes.